Medicare Enrolled
Dr. Kiem Liem, M.D.
Hematology & Oncology · Long Beach, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Liem from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Liem?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Liem
Dr. Kiem Liem is a hematology & oncology specialist in Long Beach, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Liem performed 34,514 Medicare services across 890 unique beneficiaries.
Between the years covered by Open Payments, Dr. Liem received a total of $12,851 from 63 pharmaceutical and/or device companies across 542 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Liem is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 18% volume in CA
$12,851 industry payments
Medicare Practice Summary
Medicare Utilization ↗34,514
Medicare services
Top 18% in CA for hematology & oncology
890
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,817 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
15,750 | $1 | $4 |
| Filgrastim injection (Zarxio) for white blood cells An injection of the biosimilar medication filgrastim-sndz (Zarxio) with a dosage of 1 microgram. |
8,760 | $0 | $1 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
3,270 | $36 | $161 |
| Denosumab injection (Prolia/Xgeva) | 2,220 | $18 | $81 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
918 | $0 | $0 |
| Anti-nausea injection (ondansetron/Zofran) | 904 | $0 | $0 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
410 | $14 | $93 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
305 | $68 | $341 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
288 | $41 | $180 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
272 | $12 | $81 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
215 | $18 | $88 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
181 | $56 | $269 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
156 | $121 | $606 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
129 | $1 | $4 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
116 | $40 | $216 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
112 | $1 | $22 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
111 | $26 | $147 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
101 | $11 | $69 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
68 | $26 | $220 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
65 | $2 | $9 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
47 | $25 | $109 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
41 | $1 | $6 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
32 | $80 | $481 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
29 | $25 | $134 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
14 | $109 | $474 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
57.4% high complexity
39.6% medium
2.9% routine
Industry Payment Transparency
Open Payments through 2023 ↗$12,851
Total received (2018-2023)
Avg $2,142/year across 6 years
Top 28% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
63
Companies
542
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,123 (86.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,300 (10.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$428 (3.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2023
$21
2022
$193
2021
$2,665
2020
$2,507
2019
$3,674
2018
$3,790
Payments by company (2023)
Consulting
Speaking
Meals & Travel
Research
Mirati Therapeutics, Inc.
$21
Top 3 companies account for 100.0% of 2023 payments
All-time payments by company (2018-2023) ›
Spectrum Pharmaceuticals Inc.
$1,568
Takeda Pharmaceuticals U.S.A., Inc.
$1,451
Amgen Inc.
$981
PFIZER INC.
$940
Genentech USA, Inc.
$935
Merck Sharp & Dohme Corporation
$443
Janssen Biotech, Inc.
$435
Puma Biotechnology, Inc.
$408
Lilly USA, LLC
$406
Bayer HealthCare Pharmaceuticals Inc.
$383
Daiichi Sankyo Inc.
$331
E.R. Squibb & Sons, L.L.C.
$331
Incyte Corporation
$298
TESARO, Inc.
$283
Novartis Pharmaceuticals Corporation
$266
AstraZeneca Pharmaceuticals LP
$219
Pharmacyclics LLC, An AbbVie Company
$192
Exelixis Inc.
$187
AMAG Pharmaceuticals, Inc.
$177
Seagen Inc.
$149
GENZYME CORPORATION
$144
Regeneron Healthcare Solutions, Inc.
$141
Ipsen Biopharmaceuticals, Inc
$138
Seattle Genetics, Inc.
$137
Boehringer Ingelheim Pharmaceuticals, Inc.
$122
Karyopharm Therapeutics Inc.
$122
EMD Serono, Inc.
$114
Celgene Corporation
$109
Coherus Biosciences Inc.
$97
Clovis Oncology, Inc.
$94
Eisai Inc.
$93
Astellas Pharma US Inc
$83
Gilead Sciences, Inc.
$79
GlaxoSmithKline, LLC.
$72
Helsinn Therapeutics (U.S.), Inc.
$71
BeiGene USA, Inc.
$65
Kite Pharma, Inc.
$65
Jazz Pharmaceuticals Inc.
$64
Myovant Sciences Inc.
$58
Global Blood Therapeutics, Inc.
$45
Teva Pharmaceuticals USA, Inc.
$45
ARRAY BIOPHARMA INC
$39
Emmaus Medical, Inc.
$37
Dova Pharmaceuticals
$36
Foundation Medicine, Inc.
$35
Octapharma USA, Inc.
$32
Alexion Pharmaceuticals, Inc.
$31
EUSA Pharma (US) LLC
$29
Epizyme, Inc.,
$24
AbbVie Inc.
$24
JAZZ PHARMACEUTICALS INC.
$22
Mirati Therapeutics, Inc.
$21
TerSera Therapeutics LLC
$21
TOLMAR Pharmaceuticals, Inc.
$19
MorphoSys, US Inc.
$18
SANOFI-AVENTIS U.S. LLC
$18
Taiho Oncology, Inc.
$17
Sirtex Medical Inc
$17
Rigel Pharmaceuticals, Inc.
$15
Janssen Pharmaceuticals, Inc
$15
Pharmacosmos Therapeutics Inc.
$14
BTG International, Inc.
$14
Innate Pharma, Inc
$13
Top 3 companies account for 31.1% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · ALIMTA · Abraxane · Alecensa · Aliqopa · Avastin · BAVENCIO · BENDEKA · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · CABOMETYX · CALQUENCE · CHANTIX · CYRAMZA · Cabometyx · DARZALEX · Doptelet · ELIGARD · ELIQUIS · ELITEK · ERBITUX · ERLEADA · Endari · Enhertu · FERAHEME · FOUNDATIONONE · Folotyn · GAZYVA · GILOTRIF · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · INREBIC · Imbruvica · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LENVIMA · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LORBRENA · LYNPARZA · Lenvima · Lumoxiti · MEKINIST · MONJUVI · MVASI · Monoferric · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OPDIVO · ORGOVYX · OXBRYTA · PADCEV · PROMACTA · Perjeta · Prolia · RYDAPT · Revlimid · Rubraca · SANDOSTATIN · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SUTENT · Somatuline Depot · Stivarga · Sylvant · TAZVERIK · TECENTRIQ · TUKYSA · Tavalisse · Udenyca · VARUBI · VENCLEXTA · VORAXAZE · VOTRIENT · VYXEOS · Vectibix · Vitrakvi · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xofigo · Yescarta · ZEJULA · ZEPZELCA · Zevalin · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (87%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
383
Per 100K population
3.9
County median income
$87,760
Nearest hospital
UCI HEALTH-LAKEWOOD
2.7 mi
2.7 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2023 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Liem is a mixed practice specialist, with above-average Medicare volume (top 18% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Liem experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Liem performed 15,750 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Liem receive payments from pharmaceutical companies?
Yes. Dr. Liem received a total of $12,851 from 63 companies across 542 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Liem's costs compare to other hematology & oncology specialists in Long Beach?
Dr. Liem's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Liem) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Long Beach
Browse hematology & oncology specialists in Long Beach ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Spectrum Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Spectrum Pharmaceuticals Inc.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology